

Clovis Oncology, Inc.  
Form 8-K  
June 15, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): June 11, 2015**

**Clovis Oncology, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**2525 28<sup>th</sup> Street, Suite 100**

**001-35347**  
**(Commission**

**File Number)**

**90-0475355**  
**(I.R.S. Employer**

**Identification No.)**

**80301**

**Boulder, Colorado**

**(Address of principal executive offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (303) 625-5000**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07 Submission of Matters to a Vote of Security Holders**

The Annual Meeting of Shareholders (the Annual Meeting ) of Clovis Oncology, Inc. (the Company ) was held on June 11, 2015. At the Annual Meeting, the shareholders of the Company voted on the following two proposals and cast their votes as described below.

**Proposal One**

The individuals listed below were elected at the Annual Meeting to serve a three-year term on the Company's Board of Directors.

	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Patrick J. Mahaffy	26,877,127	126,576	3,379,118
M. James Barrett	23,800,813	3,202,890	3,379,118
Thorlef Spickschen	26,849,482	154,221	3,379,118

**Proposal Two**

Proposal two was a management proposal to hold an advisory vote on the compensation of the Company's named executive officers, as described in the proxy materials. This proposal was approved.

<b>For</b>	<b>Against</b>	<b>Abstained</b>	<b>Broker Non-Votes</b>
20,548,207	6,406,786	48,710	3,379,118

**Proposal Three**

Proposal two was a management proposal to ratify the appointment of Ernst & Young LLP as auditors of the Company for fiscal year 2015, as described in the proxy materials. This proposal was approved.

<b>For</b>	<b>Against</b>	<b>Abstained</b>
30,344,403	25,592	12,826

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CLOVIS ONCOLOGY, INC.**

June 15, 2015

By: /s/ Erle T. Mast

Name: Erle T. Mast

Title: Executive Vice President and Chief Financial Officer